Reply
Abstract
We thank Hofmann and Dagi1 for their thoughtful and substantive response to our work and for expanding the discussion to include the formidable economic, regulatory, and incentive-based challenges that confront surgeon-innovators. Their articulation of the “valley of death” between proof-of-concept and patient impact is accurate, well supported, and reflective of the lived experience of many clinicians attempting to translate ideas into therapies. We fully acknowledge the magnitude of these financial and structural barriers.
Fields of Study & Subjects
Health and Medical Research Impacts
Pharmaceutical Economics and Policy
Healthcare Regulation
Publication details
- Journal / source
- JVS-Vascular Insights
- Pages
- 100358–100358
- Publication date
- 1 January 2026
- Language
- EN